It’s very interesting to see that this particular population of oligometastatic hormone-sensitive prostate cancer had a very high grade of complete biochemical response, especially if compared to the low-burden population presented in the pivotal trial in this particular kind of patients, because we saw a 92% of patients reaching a complete biochemical response rate, when actually in clinical practice a low-burden patient would have a 60% rate of complete biochemical response, so this is really interesting because it means that an oligometastatic patient, despite the number of lesions up to five, is quite different from a low-burden disease...
It’s very interesting to see that this particular population of oligometastatic hormone-sensitive prostate cancer had a very high grade of complete biochemical response, especially if compared to the low-burden population presented in the pivotal trial in this particular kind of patients, because we saw a 92% of patients reaching a complete biochemical response rate, when actually in clinical practice a low-burden patient would have a 60% rate of complete biochemical response, so this is really interesting because it means that an oligometastatic patient, despite the number of lesions up to five, is quite different from a low-burden disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
